



Vita Life Sciences Limited

ACN 003 190 421

ABN 35 003 190 421

Corporate Office

Suite 802, Level 8,
1-5 Chalmers Crescent
Mascot NSW 2020
Australia

T: 61 2 9545 2633

F: 61 2 9545 1311

vitalifesciences.com

17 June 2025

Market Announcements
Australian Securities Exchange Ltd
20 Bridge Street
Sydney, NSW 2000

GUIDANCE

Vita Life Sciences (ASX: VLS) announces the following guidance for the half year ending 30 June 2025:

Sales: \$45.0m-\$46.0m (*H1 2024: \$39.5m*)

Pre-tax Profit: \$6.2m-6.7m (*H1 2024: \$6.0m*)

The Company expects to deliver revenue growth of around 14–16% on the prior corresponding period (PCP), reflecting the strength of core markets, Australia, Malaysia and Singapore. The new distributor in China continues to successfully build sales, albeit sales to China will be lower than the PCP.

The Group continues to invest strategically in its brands, sales channels and marketing capabilities to drive market share gains and revenue growth. These investments are expensed and reflected in the Group's forecast 1st half pre-tax profit and are critical to strengthening our competitive position and unlocking long-term value across key markets.

Directors remain confident in building upon 1st half momentum in the 2nd half, as sales initiatives continue to gain traction. Overall, the Group remains focussed on its long-term strategy and remains committed to delivering sustainable growth and value for shareholders.

A handwritten signature in black ink, appearing to read 'A. O'Keefe', with a stylized flourish at the end.

Andrew O'Keefe
Managing Director

Email: enquiries@vitalifesciences.com.au